Institute backs development of drug to protect brain from radiotherapy

The National Cancer Institute gave Chrysalis BioTherapeutics $1.5 million for the continued development of Chrysalin, a regenerative peptide that could lessen radiotherapy-induced brain tissue damage. In clinical trials involving skin healing and bone repair, adverse events were not reported, said Darrell H. Carney, founder and CEO of Chrysalis.

View Full Article in:

American City Business Journals · Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN